ALLMedicine Cystinuria Center

Apr 9th, 2020 - Re: Assessment of Health-Related Quality of Life in Patients with Cystinuria on Tiopronin Therapy.|2020|Assimos DG,|

Apr 4th, 2020 - Cystinuria is an autosomal recessive disorder characterized by excessive urinary excretion of cystine, resulting in recurrent cystine kidney stones, often presenting in childhood. Current treatment options for cystinuria include dietary and/or flu...

Mar 17th, 2020 - Cystinuria is an inherited disease characterized by increased urinary cystine excretion and recurrent cystine stones. Current treatment regimens have limited effectiveness in preventing stone recurrence and are often poorly tolerated. The aim of t...

Feb 18th, 2020 - Purpose: Cystinuria is a genetic disorder with both autosomal recessive and incompletely dominant inheritance. The disorder disrupts cystine and other dibasic amino acid transport in proximal tubules of the kidney, resulting in recurrent kidney st...

Jan 12th, 2020 - The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the ...

Jun 27th, 2019 - Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatmen...

May 25th, 2020 - Boxed Warning section Physicians planning to use penicillamine should thoroughly familiarized themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should r...

Apr 9th, 2020 - Re: Assessment of Health-Related Quality of Life in Patients with Cystinuria on Tiopronin Therapy.|2020|Assimos DG,|

Apr 4th, 2020 - Cystinuria is an autosomal recessive disorder characterized by excessive urinary excretion of cystine, resulting in recurrent cystine kidney stones, often presenting in childhood. Current treatment options for cystinuria include dietary and/or flu...

Mar 17th, 2020 - Cystinuria is an inherited disease characterized by increased urinary cystine excretion and recurrent cystine stones. Current treatment regimens have limited effectiveness in preventing stone recurrence and are often poorly tolerated. The aim of t...

Feb 18th, 2020 - Purpose: Cystinuria is a genetic disorder with both autosomal recessive and incompletely dominant inheritance. The disorder disrupts cystine and other dibasic amino acid transport in proximal tubules of the kidney, resulting in recurrent kidney st...

Jul 1st, 2019 - The US Food and Drug Administration (FDA) has approved an enteric-coated delayed-release formulation of tiopronin (Thiola EC, Retrophin) for treatment of cystinuria, a rare inherited disorder that causes an increase in cystine levels in the urine,...

Jun 27th, 2019 - Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatmen...

Feb 10th, 2016 - (Reuters) - Compounding pharmacy Imprimis Pharmaceuticals Inc said on Wednesday it plans to make a cheaper alternative to Retrophin Inc’s kidney stone drug, Thiola. Retrophin, under former Chief Executive Martin Shkreli, raised the price of the dr...

Feb 13th, 2007 - Introduction Symptomatic thalamic lesions are more frequently related to stroke, usually causing contralateral sensory symptoms, and less often to contralateral movement disorders. Thalamic lesions leading to movement disorders have been reported ...